S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NYSE:NUVB

Nuvation Bio (NUVB) Stock Forecast, Price & News

$1.33
-0.06 (-4.32%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.33
$1.45
50-Day Range
$1.27
$2.10
52-Week Range
$1.18
$2.55
Volume
907,944 shs
Average Volume
885,059 shs
Market Capitalization
$291.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.38

Nuvation Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
228.9% Upside
$4.38 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Nuvation Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

217th out of 963 stocks

Pharmaceutical Preparations Industry

86th out of 458 stocks


NUVB stock logo

About Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

NUVB Price History

NUVB Stock News Headlines

BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
RBC Capital Reaffirms Their Buy Rating on Nuvation Bio (NUVB)
Nuvation Bio Insider Ups Holding During Year
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Nuvation Bio Insider Ups Holding During Year \
Nuvation Bio Inc Ordinary Shares - Class A
BTIG Reaffirms Their Hold Rating on Nuvation Bio (NUVB)
Nuvation Bio GAAP EPS of -$0.10
Analyst Expectations for Nuvation Bio's Future
Nuvation Bio (NUVB) Gets a Buy from H.C. Wainwright
Where Nuvation Bio Stands With Analysts
BTIG Keeps Their Hold Rating on Nuvation Bio (NUVB)
Wedbush Sticks to Their Buy Rating for Nuvation Bio (NUVB)
NUVB Nuvation Bio Inc.
See More Headlines
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.38
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+228.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-104,200,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
139,927,000
Market Cap
$291.19 million
Optionable
Not Optionable
Beta
0.72
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. David T. Hung M.D.Dr. David T. Hung M.D. (Age 65)
    Founder, Pres, CEO & Director
    Comp: $944.51k
  • Ms. Jennifer A. FoxMs. Jennifer A. Fox (Age 51)
    CFO & Sec.
    Comp: $834.3k
  • Dr. David C. Hanley Ph.D. (Age 53)
    Chief Technical Operations Officer
    Comp: $586.04k
  • Dr. Gary Hattersley Ph.D. (Age 56)
    Chief Scientific Officer
  • Ms. Stacy Markel (Age 58)
    Chief People Officer
  • Ms. Kerry A. Wentworth (Age 50)
    Chief Regulatory Officer
  • Dr. David Liu M.D. (Age 53)
    Ph.D., Chief Medical Officer













NUVB Stock - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVB shares.
View NUVB analyst ratings
or view top-rated stocks.

What is Nuvation Bio's stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month target prices for Nuvation Bio's stock. Their NUVB share price forecasts range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.38 in the next year. This suggests a possible upside of 228.9% from the stock's current price.
View analysts price targets for NUVB
or view top-rated stocks among Wall Street analysts.

How have NUVB shares performed in 2023?

Nuvation Bio's stock was trading at $1.92 at the beginning of 2023. Since then, NUVB stock has decreased by 30.7% and is now trading at $1.33.
View the best growth stocks for 2023 here
.

When is Nuvation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NUVB earnings forecast
.

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02.

What ETF holds Nuvation Bio's stock ?

Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio.

What is Nuvation Bio's stock symbol?

Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB."

Who are Nuvation Bio's major shareholders?

Nuvation Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (1.38%), Geode Capital Management LLC (1.25%), AWM Investment Company Inc. (0.65%), Northern Trust Corp (0.57%), Prosight Management LP (0.50%) and Charles Schwab Investment Management Inc. (0.48%). Insiders that own company stock include Fund V LP Omega, Kathryn E Falberg and Oleg Nodelman.
View institutional ownership trends
.

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvation Bio's stock price today?

One share of NUVB stock can currently be purchased for approximately $1.33.

How much money does Nuvation Bio make?

Nuvation Bio (NYSE:NUVB) has a market capitalization of $291.19 million. The company earns $-104,200,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How can I contact Nuvation Bio?

Nuvation Bio's mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The official website for the company is www.nuvationbio.com. The company can be reached via phone at 332-208-6102 or via email at ir@nuvationbio.com.

This page (NYSE:NUVB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -